Agenda Faculty Past events

9th Hybrid AFtm
Therapies Summit

Icon Calendar

June 5, 2026

Icon Location

Sitges, Spain

    June 5
  • 08:30 Welcome
  • 08:35 Introduction to the Hybrid AF Therapies Summit

    • 08:45

    Atrial Fibrillation

  • • Why Hasn’t Endocardial Ablation of the LAPW Demonstrated Benefit Over PVI?
  • • Is Repeat Catheter Ablation Delaying Definitive Therapy?
  • • Is PFA Effective in the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation?
  • • Comparative Survival Outcomes of Hybrid and Catheter Ablations: Analysis of Individual TimeTo-Event Data
  • • Q&A Open Session With Panelists
  • 10:05 Coffee Break

    • 10:35

    Hybrid AF Therapies

  • • From Paroxysmal to Advanced Substrate: Hybrid Ablation for Advanced AF in Heart Failure Patients
  • • Changes in Cardiac Mechanics After Hybrid AF Ablation
  • • All in 1: Convergent Ablation, LAA Exclusion and Endocardial PFA Ablation
  • • All in 1 : Convergent Ablation, LAA Exclusion and MIDCAB
  • • Which Patients and When? Should Hybrid Be Considered Earlier?
  • • Q& A Open Session With Panelists
  • 12:10 Lunch

    • 13:20

    Hybrid AF Therapies (cont.)

  • • Importance of Critical Mass and Epicardial LAA Exclusion
  • • Long Term Durability Matters - CEASE-AF 3 Year Results
  • • Evolution of TT-ABC (All Box Clamp) Technique
  • • Sinus Node Sparing for the Treatment of IST
  • • Future Directions in Hybrid AF Therapies / Q&A
  • 14:45 Closing & Departures
View Agenda
Agenda Download
Register Agenda

Welcome to the 9th Hybrid AF Therapies Summit

It is our pleasure to welcome you to the 9th Hybrid AF Therapies Summit at the Eurostars Hotel Sitges in Barcelona, Spain.

The summit represents a fantastic opportunity to actively participate in a highly focused, multi-disciplinary event dedicated to contemporary and emerging approaches to treating your patients with arrhythmias.

The interest in Hybrid AF Therapies is growing. There is increasing evidence that the Hybrid procedure, by combining epicardial and endocardial ablation techniques, represents a robust solution in addressing unmet clinical needs in arrhythmia treatment, from advanced forms of atrial fibrillation (AF) to inappropriate sinus tachycardia. The major cardiac societies, globally, are reflecting the acceptance of Hybrid AF Therapies in their recent treatment guidelines. Every day, more and more cardiac surgeons, electrophysiologists and cardiologists are partnering together to offer their patients the most diverse and complete range of therapeutic options.

AtriCure is proud to facilitate this event. You will have the opportunity to hear from an international faculty, exchange your experiences and engage in meaningful discussions with your peers to further advance Hybrid AF Therapies development and offer your patients effective treatment options.

Our team is honored to support this worldclass event which aligns directly with our mission: At AtriCure we are passionately focused on reducing the global atrial fibrillation epidemic and healing the lives of those affected by complex arrhythmias and pain after surgery.

Enjoy the Summit!

Program overview

    June 5
  • 08:30 Welcome
  • 08:35 Introduction to the Hybrid AF Therapies Summit

    • 08:45

    Atrial Fibrillation

  • • Why Hasn’t Endocardial Ablation of the LAPW Demonstrated Benefit Over PVI?
  • • Is Repeat Catheter Ablation Delaying Definitive Therapy?
  • • Is PFA Effective in the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation?
  • • Comparative Survival Outcomes of Hybrid and Catheter Ablations: Analysis of Individual TimeTo-Event Data
  • • Q&A Open Session With Panelists
  • 10:05 Coffee Break

    • 10:35

    Hybrid AF Therapies

  • • From Paroxysmal to Advanced Substrate: Hybrid Ablation for Advanced AF in Heart Failure Patients
  • • Changes in Cardiac Mechanics After Hybrid AF Ablation
  • • All in 1: Convergent Ablation, LAA Exclusion and Endocardial PFA Ablation
  • • All in 1 : Convergent Ablation, LAA Exclusion and MIDCAB
  • • Which Patients and When? Should Hybrid Be Considered Earlier?
  • • Q& A Open Session With Panelists
  • 12:10 Lunch

    • 13:20

    Hybrid AF Therapies (cont.)

  • • Importance of Critical Mass and Epicardial LAA Exclusion
  • • Long Term Durability Matters - CEASE-AF 3 Year Results
  • • Evolution of TT-ABC (All Box Clamp) Technique
  • • Sinus Node Sparing for the Treatment of IST
  • • Future Directions in Hybrid AF Therapies / Q&A
  • 14:45 Closing & Departures
View Agenda
Agenda Download

Countdown to event